PHA5128 Dose Optimization II Case Study 3 Spring 2013

Similar documents
PHA Spring First Exam. 8 Aminoglycosides (5 points)

Carbamazepine has a clearance of L/h/kg for monotherapy. For immediate release carbamazepine, the oral bioavailbility is 0.8

Multiple IV Bolus Dose Administration

Name: UFID: PHA Exam 2. Spring 2013

PHA 5128 Spring 2009 First Exam (Version B)

TDM of Aminoglycoside Antibiotics

SHC Vancomycin Dosing Guide

PHA 5128 Final Exam Spring 2004 Version A. On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Case Studies V (Answers)

TDM. Measurement techniques used to determine cyclosporine level include:

PHA 5128 CASE STUDY 5 (Digoxin, Cyclosporine, and Methotrexate) Spring 2007

PHA 5128 Spring 2000 Final Exam

PHARMACOKINETICS SMALL GROUP II:

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Selected Clinical Calculations Chapter 10. Heparin-Dosing calculations

Policy: Created: 2/11/2015; Approved: Adult Pharmacokinetic Dosing and Monitoring- Vancomycin Dosing

Doses Target Concentration Intervention

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Aminoglycosides. Uses: Treatment of serious gram-negative systemic infections and some grampositive

New drugs necessity for therapeutic drug monitoring

Use ideal body weight (IBW) unless actual body weight is less. Use the following equation to calculate IBW:

Gemcitabine + Cisplatin Regimen

PHA 5128 Case Study 4 (Answers) Total Cp = Unbound Cp/fu.

Full title of guideline INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS. control

Supplementary Table 1: Summary of 33 Patients Treated with Abemaciclib in Dose Escalation

TDM of Digoxin. Use of Digoxin Serum Concentrations to Alter Dosages

IV Vancomycin dosing and monitoring Antibiotic Guidelines. Contents. Intro

PHA Exam 1. Spring 2013

Basic Pharmacokinetic Principles Stephen P. Roush, Pharm.D. Clinical Coordinator, Department of Pharmacy

Career Corner: Pharmaceutical Calculations for Technicians. Ashlee Mattingly, PharmD, BCPS

. Although there is a little

TDM Lecture 7 5 th Stage. TDM of Digoxin. Uses: Digoxin is usually used in heart failure associated and atrial fibrillation.

Continuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook

A REVIEW ON DOSAGE REGIMEN

PHA Final Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Counties in the top and bottom two quintiles of both diabetes and obesity, Age-adjusted percentage of adults aged 20 years who are obese, 2007

PHA Final Exam Fall 2006

INTRAVENOUS VANCOMYCIN PRESCRIBING AND MONITORING GUIDELINE FOR ADULT PATIENTS

PHA5128 Dose Optimization II Case Study I Spring 2013

Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment

Helmut Schütz. The Global Bioequivalence Harmonisation Initiative. 12 April 2018 [Session II: Necessity of multiple dose studies in BE testing] 1

THE AMINOGLYCOSIDE ANTIBIOTICS

EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING

PHA 4120 Second Exam Key Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

pharmacy, we need to see how clinical pharmacokinetics fits into the pharmaceutical care process.

SBUH Aminoglycoside Dosing Protocol

PHAR 7632 Chapter 16

Drug Dosing in Renal Insufficiency. Coralie Therese D. Dimacali, MD College of Medicine University of the Philippines Manila

AMINOGLYCOSIDES TDM D O N E B Y

Myrna Y. Munar, Pharm.D., BCPS

Thus, we can group the entire loading dose together as though it was given as a single dose, all administered when the first dose was given.

Clinical and statistical considerations of bridging approaches to alternative dosing regimen or formulations

Adult Institutional Pharmacokinetics Protocol

Impact of hospital guideline for weight-based antimicrobial dosing in morbidly obese adults and comprehensive literature review

1. If the MTC is 100 ng/ml and the MEC is 0.12 ng/ml, which of the following dosing regimen(s) are in the therapeutic window?

MEDICATION MONITORING: Pharmacist-Managed Intravenous (IV) Vancomycin Protocol

VANCOMYCIN DOSING AND MONITORING GUIDELINES

BASIC PHARMACOKINETICS

Adjusting phenytoin dosage in complex patients: how to win friends and influence patient outcomes

BIOPHARMACEUTICS and CLINICAL PHARMACY

Understand the physiological determinants of extent and rate of absorption

General Principles of Pharmacology and Toxicology

Approved by: SMG Origination Date: 06/14 Expiration Date: 06/17 Review Date: Revision Date: POLICY and PROCEDURE Archived Date: Page 1 of 14

PHA Second Exam Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

PHA Final Exam Fall 2001

BSWH Pharmacist Continuing Education PART 5: Pharmacotherapy and Pharmacokinetics in Adults: Aminoglycosides and Vancomycin

Challenges in Therapeutic Drug Monitoring:

Learning Outcomes. Overall Picture. Part 1 Overview of Key Concepts of Clinical Pharmacokine2cs 4/23/14. A- Awaisu- A- Nader- CPPD

PHA 5127 FINAL EXAM FALL On my honor, I have neither given nor received unauthorized aid in doing this assignment.

ANTIBIOTIC DOSE AND DOSE INTERVALS IN RRT and ECMO

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Voriconazole Rationale for the EUCAST clinical breakpoints, version March 2010

HM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics>

Principal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA

Bassett Healthcare Clinical Laboratory

Basic Concepts of TDM

A Computer-based Pharmacokinetic Implementation for Digoxin Therapeutic Monitoring in Pediatric Patients

4WS Neurology. Table of Contents

NHS Grampian Staff Guidance for the Administration of Intravenous Vancomycin in Adults via Intermittent (pulsed) Infusion

Aminoglycosides John A. Bosso, Pharm.D.

(Max 2 g) = to nearest 250 mg

Pharmacokinetics Overview

PALO VERDE HEALTH CARE DISTRICT REGULAR BOARD OF DIRECTORS MEETING MINUTES July 27, 2016 City Council Chambers

John E. Murphy, PharmD, FASHP, FCCP

D DAVID PUBLISHING. 1. Introduction. Kathryn Koliha 1, Julie Falk 1, Rachana Patel 1 and Karen Kier 2

Evaluation of Vancomycin Continuous Infusion in Trauma Patients

Trust Guideline for the Use of Parenteral Vancomycin and Teicoplanin in Adults

Cystatin C: A New Approach to Improve Medication Dosing

Vancomycin Pharmacokinetics in Normal and Morbidly Obese Subjects

USES OF PHARMACOKINETICS

Vancomycin dosing in morbidly obese patients

Adult Inpatient Antibiogram. Antimicrobial Susceptibilities of Frequently Recovered Clinical Isolates. January to December 2016

CAT. Dosisaanpassing van antibiotica, toepasbaarheid van beschikbare calculators. Apr. Glynis Frans Supervisor: Prof. Apr.

EMA/EGA. Session 1: orally administered Modified Release Products European Regulatory Requirements London 30 April 2015 Dr.

Assessing Renal Function: What you Didn t Know You Didn t Know

Section 5.2: Pharmacokinetic properties

PHA Second Exam. Fall On my honor, I have neither given nor received unauthorized aid in doing this assignment.

Vancomycin Pharmacokinetics. Myrna Y. Munar, Pharm.D., BCPS Associate Professor of Pharmacy

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

PHENYTOIN DOSING INFORMATION. Adult Dosage

Transcription:

Use the vancomycin dosing nomogram table below: A female patient, 57 years of age, 5 6 in height and 100 in weight had an infection requiring vancomycin treatment. Her serum creatinine was 0.8 mg/d. What would be the recommended initial dosage of vancomycin based on the nomogram above? Using this dosing regimen, compute the expected steady-state C max and C min values for both IV bolus administration and IV infusion (assuming 1 hr infusion time). Is the therapeutic goal attained (i.e. trough concentration between 15 and 20 mg/)? IBW = 45 + 2.3(height in inches 60) = 45 + 2.3(66 60) = 58.8 ABW = IBW + 0.4(TBW IBW) = 58.8 + 0.4(100 58.8) = 75.3 We will use the adjusted body weight (ABW) given that the total body weight (TBW is more than 120% of the ideal body weight (IBW). Vancomycin is primarily cleared via the kidney. We can compute its clearance using the creatinine clearance estimation. C cr (female) = 75.3(140 57) 0.8(85) = 91.9 m/min Based on the nomogram, you will use 1000 mg q8h dosing regimen. To compute the steady concentrations, first transform the clearance to /h unit. C = 91.9 m min 1 1000m 60min = 5.51 hr h V d = 0.17(age in yrs) + 0.22(TBW in ) + 15 = 0.17(57) + 0.22(100) + 15 = 46.7 1

k = C = 5.51 = 0.118 h 1 V d 46.7 For IV bolus, C max,ss = For IV infusion, C max,ss = S F dose V d 1 1 exp( kτ) = 1(1)(1000) 1 mg = 35 46.7 1 exp( 0.118 8) C min,ss = C max,ss exp( kτ) = 35 exp( 0.118 8) = 13.6 mg S F dose C 1 exp( kt) 1 exp( kτ) = 1(1)(1000) 1 exp( 0.118 1) mg = 33.1 5.51 1 exp( 0.118 8) C min,ss = C max,ss exp( kτ) = 33.1 exp( 0.118 7) = 14.5 mg Both steady C min for IV bolus and IV infusion are below the 15 to 20 mg/ range. Therapeutic goal is not attained. 2

While on vancomycin, a male patient, 46 years of age, 6 3 in height, weighing 147, had a loss of volume of distribution of 10% and a corresponding increase in serum creatinine level by 30%. Adjust his vancomycin dosage, assuming that his previous serum creatinine was 1.3 mg/d. The MIC of vancomycin against his infection was 0.5 mg/. Compute the steady state Cmax and Cmin based on IV bolus administration. With the dosing regimen that you have recommended, are the first dose Cmin and the steady state Cmin values consistently above MIC? Do you need to adjust the dosing frequency based on the computation that you have obtained so that the trough is below 25 mg/ and between 15 to 20 mg/? Estimate the AUC to MIC ratio of vancomycin for the patient s altered condition, assuming that vancomycin is administered as an IV bolus and follows a 1 compartment body model (Hint: use the equation AUC = C ss,max /k e to estimate this ratio. V d (in ) = 0.17(46) + 0.22(147) + 15 = 55.2 New V d = 0.9 V d = 49.7 IBW = 50 + 2.3(75 60) = 84.5 ABW = 84.5 + 0.4(147 84.5) = 109.5 C cr,male = New C cr = (140 46) 109.5 72(1.3) = 110 min (140 46)109.5 72 1.3 1.3 = 84.6 min For both conditions, the recommended dosing regimen for vancomycin is 1000 mg q8h. No need to adjust his dosing regimen. C = 84.6 m min 1 1000 m 60min = 5.076 /h h k = 5.076 /h 49.7 = 0.102 h 1 3

For IV bolus, C max,ss = 1000 49.7 1 mg = 36.1 1 exp( 0.102 8) C min,ss = 36.1 exp( 0.102 8) = 16 mg The steady state trough concentration is below 25 mg/ and is within the 15 to 20 mg/ range. There is no need to change dosage. The AUC to MIC ratio is: The therapeutic goal is achieved. AUC = 36.1 = 353.9 mg. h/ 0.102 AUC MIC = 353.9 = 707.8 > 400 0.5 4

A female patient, 49 years of age, 78 in weight, is started on intravenous phenobarbital sodium. The normal therapeutic range for this medication is between 10 and 30 mg/. A loading dose was administered to achieve a drug plasma concentration at t=0 of 30 mg/. Calculate what the loading should be to achieve a target concentration of 30 mg/ and the daily maintenance dose to produce an average steady state phenobarbital concentration of 25 mg/. Note that the dose should be computed for phenobarbital sodium. V d = 0.7 78 = 54.6 C = 4 m h The salt factor for phenobarbital sodium is 0.9. The compute the loading dose, D = MD = C C p τ F S m 78 = 312 h = 13 day V C 54.6 30 = = 1820 mg ~ 2000 mg F S 1 0.9 = 13 mg 25 day 1day = 361 mg ~ 400 mg/day 1 0.9 Note that maintenance dose should be based on dose per day. 5

A 59 year old male patient of 87 weight is to receive carbamazepine regimen. Compute the daily oral dose (for immediate release formulation) to achieve an average steady state plasma concentration of 6.0 mg/, assuming monotherapy (i.e. no concomitant medication). In the second scenario, the same male patient received 1.5 mg/ by body weight phenobarbital q12h for the past 12 months without any success in controlling his seizures. The medical practitioner decided to start this patient on a concomitant therapy with carbamazepine. Compute the daily maintenance dose to achieve a target steady state concentration of 6.0 mg/ using the immediate release formulation. His blood sample after being on a maintenance regimen of carbamazepine showed a level of 11 mg/ carbamazepine. Compute the dose adjustment so that the patient gets the desired plasma concentration of 6.0 mg/. Carbamazepine C in monotherapy is 0.064 / Dose = C p,ss C τ 6.0 0.064 87 24 = F S 0.8 1 For polytherapy, carbamazepine C is 0.1 / 6.0 0.1 87 24 MD = 0.8 1 = 1002.24 mg~1000 mg = 1566 mg mg ~1500 day day Using proportionality ratio to compute the dose adjustment, 11 mg 6 mg = 1500 mg x x = 818 mg ~800 mg 6